Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

29.49 -0.22 (-0.74%)
Streaming Delayed Price Updated: 11:57 AM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes Plc

< Previous 1 2 3 4 5 6 7 Next >
Alkermes Plans Separating Its Oncology Unit; Lifts FY22 Earnings Guidance
Via Benzinga
Recap: Alkermes Q3 Earnings
Alkermes (NASDAQ:ALKS) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Alkermes missed estimated... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2022
Upgrades 
Via Benzinga
Domino's Pizza To Rally 20%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised Domino's Pizza, Inc. (NYSE: DPZ) price target from $370 to $400. Wedbush analyst Nick Setyan maintained an Outperform rating on the stock. Domino's shares rose 10.4% to close at $333.26... 
Via Benzinga
Recap: Alkermes Q2 Earnings
  Alkermes (NASDAQ:ALKS) reported its Q2 earnings results on Wednesday, July 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022
  
Via Benzinga
Looking Into Alkermes's Return On Capital Employed
According to data from Benzinga Pro, during Q2, Alkermes's (NASDAQ:ALKS) reported sales totaled $276.22 million. Despite a 16.06% increase in earnings, the company posted a loss of $30.14 million. 
Via Benzinga
Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Preview: Alkermes
Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-07-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will... 
Via Benzinga
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
The group has several commonalities, including strong ratings and promising charts. 
Via Investor's Business Daily
Sarissa Capital Comments on Alkermes Annual Meeting
From Sarissa Capital Management LP
Via Business Wire
Northrop Grumman Leads 5 Defensive Plays Near Buy Points
Northrop headlines 5 stocks near buy points with the mettle to withstand a recession. 
Via Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92. 
Via Investor's Business Daily
4 Biotech Stocks With Bright Prospects To Buy Amid Recovery
New drug approvals, acquisitions, and other pipeline developments are back in the spotlight in the biotech industry, following the focus on the development of vaccines and antibody treatments for... 
Via Talk Markets
Alkermes Announces 2022 Alkermes Inspiration Grants® Program to Support Innovative Programs Focused on People Affected by Addiction, Serious Mental Illness or Cancer
SOURCE: Alkermes 
Via 3BL Media
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
Biotech stocks reversed course along with the broader market and closed the week ending June 3 lower. The sector's lean run thus got extended. 
Via Benzinga
Best Stocks To Buy Now: June 02, 2022
The stock market continues to be one of the best ways for regular investors to build wealth over time. The 
Via Best Stocks
Topics Artificial Intelligence Cannabis
Exposures Artificial Intelligence Cannabis
Sarissa Condemns Poor Corporate Governance at Alkermes
From Sarissa Capital Management LP
Via Business Wire
New Findings About Life With Bipolar 1 Disorder
SOURCE: Alkermes 
Via 3BL Media
Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
Via FinancialNewsMedia
Exposures COVID-19
Treating Bipolar 1 Disorder
SOURCE: Alkermes 
Via 3BL Media
Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing... 
Via Talk Markets
Alkermes Awarded 2022 Platinum Bell Seal for Workplace Mental Health
SOURCE: Alkermes 
Via 3BL Media
Tips to Improve Mental Well-Being
SOURCE: Alkermes 
Via 3BL Media
Alkermes Celebrates National Women's Health Week by Reminding You Why Regular Cancer Screenings Are Vital
SOURCE: Alkermes 
Via 3BL Media
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
SOURCE: Alkermes 
Via 3BL Media
Looking Into Alkermes's Return On Capital Employed
Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter. 
Via Benzinga
61 Biggest Movers From Yesterday
Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with... 
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.